CRP and idiopathic interstitial pneumonia: In the INMARK trial, a phase 3 RCT of nintedanib therapy for IPF patients with a diagnosis made within the previous 3 years and more than 80% of FVC, the product of C-reactive protein degraded by matrix metalloprotease was associated with changes in FVC for 52 weeks but not the reducing rate of decrease in FVC by nintedanib17.